Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05358860
Other study ID # Sofwave09
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 1, 2022
Est. completion date December 31, 2022

Study information

Verified date April 2023
Source Sofwave Medical LTD
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Open-label, non-randomized, prospective, multi-center, self-controlled clinical study with masked evaluation.


Description:

Eligible patients will receive 3 treatments (4-6 weeks apart) on the facial acne scars using Sofwave System. Treatment may be administered after the enrollment and screening at the first visit, or it may occur later following the enrollment and screening activities based on site scheduling availabilities. All patients will return to the clinic for one follow up visit at 3 months ± 3 weeks post last treatment (FU1). Methodology described in the protocol to evaluate efficacy and safety of treatments will be carried out at each visit at the clinic.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 22 Years to 80 Years
Eligibility Inclusion Criteria: 1. Healthy male or female subjects > 22 years of age and < 80 years of age. 2. For female subjects, not pregnant or lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide) or abstinence. 3. Seeking treatment for facial acne scars. 4. Have visible mild to moderate facial acne scars. 5. Agree not to undergo any other facial acne scars treatments for a period of 3 months following Sofwave treatments. 6. Willing to have photographs of the treated areas. Agree for de-identified study images to be used in evaluations, publications and presentations. 7. Able and willing to comply with all visits, treatments and evaluations schedules and requirements. 8. Able to understand and provide written Informed Consent Exclusion Criteria: 1. Pregnant or planning to become pregnant during the duration of the study, having given birth less than 3 months ago, and/or breast feeding 2. Current smoker or has history of heavy smoking (25 cigarettes per day or more) in past 10 years. 3. History of severe migraine tendency. 4. History of Epileptic seizures. 5. History of chronic drug or alcohol abuse. 6. Taking Isotretinoin or other oral retinoid within the past 6 months; taking anti-platelet or anti-coagulant within the past 2 weeks. 7. Medical disorder that may hinder the wound healing or immune response (such as blood disorder, inflammatory disease, etc.) 8. Presence of a metal stent or implant in the facial area. 9. Known allergy to tetracaine, Xylocaine or epinephrine. 10. Active malignancy or history of malignancy in the past 5 years. 11. Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders (i.e. any disease state that in the opinion of the investigator may interfere with the anesthesia, treatment, or healing process). 12. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications. 13. Presence of any active systemic or local infections. 14. Severe or cystic facial acne, acutance uses during past 6 months. 15. History of cosmetic treatments in the facial area to be treated, including facial skin-tightening procedure within the 6 months; injectable (Botox or fillers of any type) within the 6 months; ablative or non-ablative resurfacing/rejuvenation laser treatment or light treatment within the past 6 months, dermabrasion or deep facial peels within the past 12 months; facelift or blepharoplasty within the past 12 months. 16. Inability to understand the protocol or to give informed consent 17. On-going use of psychiatric medication 18. Unable or unwilling to comply with the study requirements and procedures 19. Currently enrolled in a clinical study of any other unapproved investigational drug or device 20. As per the investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Sofwave
The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.

Locations

Country Name City State
United States SLSS, a Division of Schweiger Dermatology Group Research Office Hackensack New Jersey
United States Laser & Skin Surgery Center of New York® New York New York
United States New York Laser & Skin Care New York New York
United States UnionDerm New York New York

Sponsors (1)

Lead Sponsor Collaborator
Sofwave Medical LTD

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of change of acne scars appearance, as assessed by independent masked evaluators at 3 months post last treatment session. following Sofwave treatments based on 6 points simplified Acne Severity Scale (ASS), as evaluated by independent masked reviewers. 1 year
See also
  Status Clinical Trial Phase
Completed NCT04559022 - Pilot Study Investigating the Efficacy of Fat Grafting as a Treatment for Male and Female Facial Acne Scarring N/A
Active, not recruiting NCT06192550 - Functional Usability and Feasibility Testing of the Profound Matrix™ System N/A
Recruiting NCT05362929 - Efficacy and Tolerability of a Hybrid Fractional Laser for the Treatment of Acne Scars in Patients With Skin of Color N/A
Recruiting NCT05597267 - The MIRIA Acne Scar Study N/A
Completed NCT05691049 - Evaluation of Efficacy and Safety of HCC_45 for the Correction of Acne Scars of the Face N/A
Active, not recruiting NCT02592993 - Performance of PicoWayTM Picosecond Fractional Laser for Acne Scars N/A
Completed NCT04827680 - Clinical Evaluation of the Safety and Performance of FRF for the Treatment and Reduction of Acne Scarring N/A
Completed NCT03988049 - Comparison of 1,550 and 755 Laser in a Split-face Trial N/A
Not yet recruiting NCT05597813 - Topical Timolol 0.5% in Atrophic Acne Scar N/A
Completed NCT03284333 - enLighten Laser With MLA Handpiece for Treatment of Moderate and Severe Acne Scars N/A
Completed NCT03514771 - Early Non-Ablative Fractional Laser Resurfacing for Acne Scars After Treatment With Oral Isotretinoin N/A
Not yet recruiting NCT06102343 - Safety and Efficacy Investigation on the Effects of ClearSkin Non-ablative ER:Glass 1540nm Laser Module in the Treatment of Acne Scars. N/A
Not yet recruiting NCT05600075 - Microneedling With Topical Preparations in the Treatment of Atrophic Post-acne Scars N/A
Not yet recruiting NCT04252352 - Treatment of Acne Scars With Fractional CO2 Laser Versus Radio-frequency Microneedling N/A
Completed NCT04606134 - Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring N/A
Completed NCT04057768 - Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles N/A